clinical_trials
Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis
Confidence86·multiple reportsImportance88NP-EVT-20261027-8DADCC8
(MedPage Today) -- The investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib may curb chronic active lesions in multiple sclerosis (MS), data from phase III trials suggested. Two MRI biomarkers in MS are slowly expanding lesions...
Read the original at the primary source
Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis
10/27/2026, 9:21:43 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —